The estimated Net Worth of Yoseph Bornstein is at least $1.61 Milion dollars as of 19 October 2020. Mr. Bornstein owns over 4,881 units of Microbot Medical Inc stock worth over $224,505 and over the last 7 years he sold MBOT stock worth over $1,383,786. In addition, he makes $0 as Independent Director at Microbot Medical Inc.
Yoseph has made over 27 trades of the Microbot Medical Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 4,881 units of MBOT stock worth $38,755 on 19 October 2020.
The largest trade he's ever made was selling 53,000 units of Microbot Medical Inc stock on 3 October 2017 worth over $63,600. On average, Yoseph trades about 24,577 units every 34 days since 2017. As of 19 October 2020 he still owns at least 242,028 units of Microbot Medical Inc stock.
You can see the complete history of Mr. Bornstein stock trades at the bottom of the page.
Yoseph Bornstein serves as Independent Director of the Company. Mr. Bornstein is a co-founder of Microbot Israel and has been a member of the Board of Directors since Microbot Israel was founded in November 2010. Mr. Bornstein founded Shizim Ltd., a life science holding group in October 2000 and has served as its president since then. Mr. Bornstein is the Chairman of GCP Clinical Studies Ltd., a provider of clinical research services and educational programs in Israel since January 2002. He is the Chairman of Biotis Ltd., a service company for the bio-pharmaceutical industry, since June 2000. In addition, he is the Chairman of Dolphin Medical Ltd., a service company for the medical device industry, since April 2012, and the Chairman of ASIS Enterprises B.B.G. Ltd., a business development company focusing on creating business ties between Israeli and Japanese entities, since August 2007. Mr. Bornstein is a co-founder and director of XACT Robotics Ltd., an Israeli- based private company seeking to develop a novel platform technology for robotic needle steering in minimally invasive interventional procedures, and is the founder of ShizimXL Innovation Center. In October 1992, Mr. Bornstein founded Pharmateam Ltd., an Israeli company that specialized in representing international pharmaceutical companies which was sold in 2000. Mr. Bornstein is also a founder of a number of other privately held life-science companies. Mr. Bornstein served as the Biotechnology Committee Chairman of the Unites States-Israel Science & Technology Commission (the “USISTF”) from September 2002 to February 2005 as well as a consultant for USISTF from September 2002 to February 2005. He is also the founder of ILSI-Israel Life Science Industry Organization (who was integrated into IATI) and ITTN-Israel Tech Transfer Organization. The Company believes that Mr. Bornstein is qualified to serve as a member of the Board due to his extensive experience in, and knowledge of, the life sciences industry and international business.
Yoseph Bornstein is 62, he's been the Independent Director of Microbot Medical Inc since 2016. There are 1 older and 11 younger executives at Microbot Medical Inc. The oldest executive at Microbot Medical Inc is Prof. Moshe Shoham, 69, who is the Co-Founder, Scientific Director & Member of Scientific Advisory Board.
Yoseph's mailing address filed with the SEC is C/O MICROBOT MEDICAL INC., 288 GROVE STREET, SUITE 388, BRAINTREE, MA, 02184.
Over the last 8 years, insiders at Microbot Medical Inc have traded over $5,894,432 worth of Microbot Medical Inc stock and bought 10,000 units worth $11,000 . The most active insiders traders include Yoseph Bornstein, Investment Management Ltd A... a Moshe Shoham. On average, Microbot Medical Inc executives and independent directors trade stock every 37 days with the average trade being worth of $46,188. The most recent stock trade was executed by Yoseph Bornstein on 19 October 2020, trading 4,881 units of MBOT stock currently worth $38,755.
microbot medical was founded with the vision of pioneering micro invasive surgery, transforming one of the biggest trends in healthcare - minimally invasive surgery (estimated to be close to $20b by 2015); the company will provide transformational micro invasive technologies with the accuracy of robots and automated instruments to assist physicians in targeting the disease site with exquisite precision. microbot will solve one of the largest unmet needs in the medical field, where morbidity as a result of surgery is more frequently due to trauma involved in gaining access to the area to perform the intended procedure rather than from the procedure itself. through its unique platforms, microbot will reach multiple surgical spaces, capitalizing on the fact that minimally invasive techniques have been applied to most of the surgical specialties. microbot’s virob platform is an autonomous advancing micro robot (aamr), less then 1mm in diameter, which has the ability to advance (forward/bac
Microbot Medical Inc executives and other stock owners filed with the SEC include: